INTRODUCTION
The search for an oral form of insulin has been under¬ way since Banting & Best (1922) gave a pancreatic extract to a diabetic dog by stomach tube and observed a reduction in blood glucose from 23 to 15-5 mmol/1 in 4h. Oral insulin would not only free diabetic patients from some of the daily injections but would also provide a more physiological route of administration. Insulin absorbed from the intestinal tract, like normal insulin secreted by the pancreas, drains primarily into the hepatic portal vein to exert its initial effect on the liver. Some will find its way into the peripheral circulation via lymphatic channels. In contrast, injected insulin is drained entirely into the peripheral circulation and has access to all parts of the body. These considerations have encouraged a search for an oral route for insulin, in spite of the formidable barriers of powerful digestive enzymes in the gastro¬ Moore, 1959; Cho & Flynn, 1990) , emulsification of insulin with a mixture of lipids (e.g. Shichiri, Shimizu, Yoshida et al. 197 ; Cho & Flynn, 1990) , coadministration of surfactants (e.g. Galloway & Root, 1972; Touitou, Donbrow & Rubinstein, 1980; Touitou & Rubinstein, 1986) or other absorption adjuvants (e.g. Nishihata, Rytting, Kamada & Higuchi, 198lb) , or coating the insulin with protective polymers (e.g. Touitou & Rubinstein, 1986;  Damgé, Michel, Aprahamian & Couvreur, 1988; Gwinup & Elias, 1990) .
The variable delivery of insulin by oral adminis¬ tration in liposomes was attributed either to régurgi¬ tation of the dose to the mouth (Weingarten et al. 1981) or to absorption through the gastric epithelium (Tragl et al. 1979; Axt et al. 1982) , rather than absorp¬ tion in the intestine. Unfortunately, none of the studies included measurement of hepatic portal vein insulin as an index of intestinal absorption. Portal insulin should be higher than peripheral values after absorption from the intestine, but not after buccal absorption. Measurement of gastric vein insulin should be highest after gastric absorption. In one of the studies with liposomal insulin, the portal vein of the experimental dogs was cannulated, but the cannula was apparently used only for the administration of insulin, rather than to obtain portal blood samples for assay (Patel et al. 1982) . Although peaks of plasma insulin and decreases in plasma glucose were seen in many instances, the effects were unpredictable and short-lived. Sustained decreases in the hyperglycaemia after oral insulin were seen only after single doses in polyalkylcyanoacrylate nanoparticles in rats (Damgé et al. 1988) or after multiple doses in human subjects of insulin in a lipid emulsion containing an inhibitor of proteolysis (Cho & Flynn, 1990) .
Our approach to oral insulin differs in several ways from previous attempts. To overcome the digestive barrier, the gelatin capsule containing insulin was pro¬ tected by a coating of an azopolymer which resists digestive enzymes, but is degraded by bacterial action in the colon. The azopolymer is a relatively impervious terpolymer of styrene, hydroxyethylmethacrylate and , '-bis (ß-styrylsulphonyl)-4,4'-diaminoazobenzene as a cross-linking agent (Kumar, Savariar, Saffran & Neckers, 1985) . The proposed mechanism for delivery of insulin involves the reduction of the azo func¬ tionalities of the azopolymer in the upper colon by resident microflora, breaking the cross-links in the polymer and changing the polymer coat to a porous form, thereby allowing water to enter the capsule and extract the insulin. The azopolymer was shown previously to be able to deliver vasopressin and insu¬ lin after oral administration in rats (Saffran, Kumar, Savariar et al. 1986 ). To overcome the lack of a trans¬ port mechanism for insulin, relatively high doses (66-400 nmol/kg) of insulin plus an enhancer of insulin absorption, 5-methoxysalicylate (Nishihata et al. 1981 (Rojdmark, Bloom, Chou & Field, 1978a (1985) and Faloona & Ungar (1972) respectively. The 30 kDa antibody to glucagon is said to be specific for pancreatic glucagon but probably responds to other glucagon-like substances. The coef¬ ficients of variation of the measurements were calcu¬ lated from the samples taken during the control period: plasma glucose, 9-4%; plasma insulin. 52-4%; plasma GLI, 23-6%; plasma flow, 27-5%; hepatic glucose production, 62-8%. The error in the insulin radioimmunoassay is large because most assays were conducted on samples obtained from diabetic dogs, with levels near the lower limit of detection of the radioimmunoassay. The calculation of hepatic glucose production uses data from two flow probes and three blood sampling sites. Figure 2 illustrates the results after oral administration in the same dog of 168 and 215 nmol/insulin kg in coated and uncoated capsules respectively. The pre-dose level of portal plasma insulin (Fig. 2a) was 26-0 + 5-56 pmol/1 (w = 3; 95% confidence limits = 2-1-49-9). The mean level after oral insulin in uncoated capsules from 1 to 7 h was not significantly different from the pre-dose value (mean = 26-5+ 2-80 pmol/1; n = 9; 95% confidence limits = 20-1-33-0). In contrast, after oral insulin in capsules coated with azopolymer the level of portal plasma insulin reached a peak of 80 pmol/litre 2-5 h after administration, returning to pre-dose values at 3 h. The pre-dose arterial plasma glucose level (Fig. 2b) was 16-1 ±0-52 mmol/1 (n = 3; 95% confidence limits= 10-6-21-6). Uncoated insulin decreased arterial plasma glucose between 1 and 2-5 h, with a just significant and steep nadir of 10-6 mmol/1 at 2h, returning quickly to pre-dose values at 3-5 h. Insulin in coated capsules was followed by a slowly developing fall in arterial plasma glucose beginning at 1-5 h, with a nadir of 10 mmol/1 at 4 h, returning to a pre-dose value at 7 h. Hepatic glucose production (Fig. 2c) (Fig. 2d) after oral insulin in uncoated capsules decreased steadily from a high of 20 ml/kg per min at -1 h to a low of 10 ml/kg per min at 4 h, although a pause in the fall occurred between 1-5 and 3 h. After oral insulin in coated cap¬ sules, there was a nadir of 9 ml/kg per h at 2 h. The mean pre-dose level of portal plasma GLI (Fig. 2e (Fig. 3a) , and a fall to pre-dose levels at about 3-5 h (Fig. 3a) . However, when each of the nine dogs in which insulin appeared in the portal plasma was used as its own control, there was a The decrease in arterial plasma glucose from a pre¬ dose mean of 21-3 + 0-91 to a mean post-dose nadir of 16-7+ 1-72 mmol/1 was not significant. The mean time of the nadir was 31 h (Fig. 3b) . Hepatic glucose pro¬ duction could be calculated in seven dogs. It fell from a pre-dose mean of 15-1 + 3-1 pmol/kg per min to a nadir of -0-7+ 13-2 (Fig. 3c) . The mean time of the nadir was 2-6 h. The pulsatile nature of hepatic glucose production is evident. Hepatic plasma flow decreased, but not significantly, from a pre-dose mean of 21-2+1-9 ml/kg per min to a nadir of 15-7+2-5.
The mean time of the nadir was 1 -9 h, coinciding with the peak in portal plasma insulin (Fig. 3d) . Portal plasma GLI decreased from a pre-dose level of 316 + 27 ng/1 to a nadir of 99 ±37 at a mean time of 3 h (Fig. 3e) . The nadirs were significant when each dog was used as its own control.
The mean times of the peaks or nadirs after oral administration of a single dose of insulin in azopolymer-coated capsules increased in the order: insulin (1-9 h) = hepatic plasma flow (1-9 h)< hepatic glucose production (2-6 h)< portal plasma GLI (30 h) < arterial plasma glucose (3-1 h).
In two dogs to which different single doses of insu¬ lin were given, there was no correlation between the dose and the magnitude of any response. For example, a dose of 30 U/kg resulted in a fall in glucose levels of 5-2 mmol/1 and a dose of 52 U/kg in a fall of 4-7 mmol/1.
Multiple doses of insulin capsules
Four diabetic dogs were used in nine experiments in which multiple oral doses of insulin between 35 and 400 nmol/kg in azopolymer-coated capsules were administered at 1-5-h intervals. Figure 4 illustrates the responses of one of these dogs to repeated oral doses of 402 nmol insulin/kg. Portal plasma insulin (Fig. 4a) increased to peaks of about 265 pmol/1 after each dose of insulin. The mean peak in arterial plasma was 168 pmol/1, or about 60% of the level in the portal plasma. Arterial plasma glucose (Fig. Ab) decreased from a mean pre-dose value of 21-9 + 0-66 mmol/1 to a low of 9-6 at the end of the experiment, a decrease to 43-5% of the pre-dose value. Figure 4c illustrates the decrease in hepatic glucose production from a pre¬ dose mean of 39-5 + 1-11 pmol/kg per min to a postdose mean of 7-7 ± 204. There were periodic rebounds to about 17 pmol/kg per min. Hepatic plasma flow (Fig. Ad) decreased from a pre-dose mean of 22-6 + 4-7 ml/kg per min to a mean of 154 + 0-9 in the post-dose period. Portal plasma GLI decreased from a pre-dose mean of 479 + 34 to a post-dose mean of 400 r (a) 113 ±16-7 ng/1 (Fig. Ae) . In this dog, as in other diabetic dogs, the pre-dose levels of portal GLI fluctuated widely, with a coefficient of variation of 50%.
The decrease in the level of arterial plasma glucose after 5 h of multiple oral insulin in azopolymer-coated capsules was dose-dependent. Data obtained with three dose levels in the same dog are illustrated in Figure 5 . While a dose of 64 nmol/kg had little effect on plasma glucose, a dose of 131 nmol/kg decreased it at 5 h to 64% of the value at 0 h, and a dose of 402 nmol/kg decreased plasma glucose at 5 h to 36%
of the value at 0 h. DISCUSSION Does the azopolymer deliver oral insulin in the dog?
The azopolymer delivery system delivered oral pep¬ tides in the rat (Saffran et al. 1986 ), but had not been tested in other species. In the present study the azo¬ polymer clearly delivered oral insulin in the dog, because treatment was followed by increases in portal vein insulin and by the metabolic consequences of its absorption, primarily on the liver. However, there was no clear dose-response relationship between the amount of insulin administered as a single oral dose What dose range of oral insulin is effective in the dog? In the rat, with a colonie diameter of only a few milli¬ meters, a dose of about 6 nmol/kg resulted in a sub¬ stantial reduction in plasma glucose (Saffran et al. 1986 ). The colon of the dog is about ten times larger than that of the rat and would therefore dilute a delivered dose of insulin by a greater volume of intes¬ tinal contents. Accordingly larger doses might be needed in the dog than in the rat. This is consistent with the results of the present study in which the effec¬ tive dose in the dog was approximately ten times that in the rat.
What are the effects of oral insulin on glucose metabolism?
In our previous work in the rat (Saffran et al. 1986 ), the only index of insulin absorption was plasma glucose. In the present study in dogs, five indices were followed: there were changes in plasma insulin, plasma glucose, hepatic glucose production, hepatic plasma flow and plasma GLI. The hypoglycaemic response to a single oral dose of insulin was limited, as was the fall in hepatic secretion of glucose. Hepatic blood flow was decreased, probably as a consequence of the effect on plasma GLI.
What is the response of plasma glucagon-like material, presumably of the gut origin, to oral insulin? The effect of oral insulin on the plasma concentration of GLI of enterai origin has not been studied pre¬ viously. Oral insulin was consistently followed by a fall in plasma GLI. If gut glucagon is a driving force in the maintenance of hyperglycaemia, the suppression of glucagon secretion by oral insulin would contribute to the decrease in hepatic production of glucose. In this initial study, there was no attempt to characterize the nature of the GLI in the plasma. Some of the values were very high (Fig. 3e) , suggesting that the assay was responding to a mixture of many products of the preproglucagon made in the alimentary canal.
However, there was a consistent fall in GLI after the oral administration of insulin. A more detailed study of the phenomenon is needed to decide whether the effect of oral insulin is on the secretion of all GLI sub¬ stances derived from the precursor, or on the cleavage to the various products. Intralumenal administration of glucose into the dog intestine elevated the secretion of all products of the preproglucagon gene (Namba et al. 1990 ).
Portal vein and injected insulin Pancreatic insulin is normally secreted into the portal circulation and inhibits hepatic glucose production.
The liver extracts a variable amount of the insulin, typically about 50%, and passes the rest into the per¬ ipheral circulation. The portalperipheral ratio of plasma insulin is about two during periods of insulin secretion. The physiological hypoglycaemic action of insulin is due to the shutdown of hepatic glucose pro¬ duction, aided by increased glucose utilization caused by lower levels of insulin in the peripheral circulation. In contrast, when insulin is injected s.c, the physio¬ logical relationship between hepatic portal and peripheral insulin does not exist because the concen¬ trations of insulin in the portal and peripheral plasma are approximately equal at all times. Much of the hypoglycaemic response to injected insulin is due to its action on peripheral tissues. Injected insulin yields higher than physiological concentrations of insulin in the peripheral circulation. Oral administration of insulin and absorption from the gastrointestinal tract into the portal circulation mimics the normal physio¬ logical process and may therefore provide better control of glucose homeostasis without concomitant peripheral hyperinsulinaemia. This may be important because hyperinsulinaemia has been suspected to be a factor in some of the cardiovascular complications of diabetes (Saffran, 1989; Gwinup & Elias, 1990; Kaplan, 1991 (Fig. Ab) because of the persistent inhibition by insulin of glucose pro¬ duction by the liver (Fig. 4c) and the utilization of plasma glucose by insulin-independent peripheral tissues, such as the brain. The fall in plasma glucose is dose-related (Fig. 5) .
Insulin-like effects of controls 
Transit time
The peak in portal vein insulin and the greatest effect on hepatic glucose production occurred at about 1-5 h after the dose, which coincides with the mouth-tocaecum transit time in the dog (Dressman, 1986) . The delay in insulin delivery by the mouth-to-caecum transit time would have to be taken into consideration in designing a daily schedule of meals and insulin administration if oral insulin delivery via the colon were to achieve therapeutic usefulness. When uncoated insulin capsules were used in control exper¬ iments, the metabolic effects occurred earlier (Fig. 2) (Gwinup & Elias, 1989; Cho & Flynn, 1990) , using other strategies to protect the insulin against digestion, encourage further work on oral insulin. The insulin capsules used in this paper contained stoichiometric amounts of sodium bicarbonate and 5-methoxysalicyclic acid. 5-Methoxysalicylate enhances absorption of insulin from the rectum (Nishihata, Rytting, Higuchi & Caldwell, 1981a) and the intestine (Nishihata et al. 198le ) of the rat after direct instil¬ lation. We chose to use 5-methoxysalicylate as an absorption enhancer because surfactants, such as bile salts, which also enhance absorption, apparently cause damage to the absorbing mucosa. The develop¬ ment of more efficient absorption enhancers than 5-methoxysalicylate may improve bioavailability.
The mixture of sodium bicarbonate and 5-methoxysalicylic acid in the capsule helps to deliver insulin in other ways. Degradation by bacterial reduction con¬ verts the azopolymer coating into a water-permeable hydrogel. When water penetrates the hydrogel coating and the gelatin capsule and wets the mixture of bicar¬ bonate and acid in the capsule, carbon dioxide is evolved. The gas pressure ruptures the gelatin capsule to release the insulin in a bolus, thereby creating a high local concentration in the colon to facilitate dif¬ fusion into the blood. In addition, salicylate has been shown to prevent the aggregation of insulin into higher molecular weight units, which would impede its absorption (Touitou, Alhaique, Fisher et al. 1987 ).
Clinical significance At first glance the high doses of insulin used in this study would seem to rule out clinical utility of the data. Indeed the bioavailability is below 1%. Satisfactory administration of insulin to human subjects by the nasal route with 10-20% bioavailability was achieved when bile salts were used as absorption adjuvants (Moses, Gordon, Carey & Flier, 1983 Plasma flow and glucagon The decrease in hepatic plasma flow after oral insulin has not, to our knowledge, been observed previously.
There is evidence for a correlation between the amount of glucagon injected into dogs and blood flow through the hepatic vascular beds (Kock, Roding, Hahnloser et al. 1970; Bashour, Genmei, Nafrawi & Downey, 1973) . In our experiments, the decrease in plasma GLI and hepatic plasma flow occurred together, suggesting that the fall in glucagon concen¬ tration may be responsible for the reduction in hepatic flow.
In these pancreatectomized dogs the gut is the major, if not the only, source of glucagon. The effect of insulin on plasma glucagon of gut origin in pancreatectomized dogs is controversial. Some (Lussier & Hetenyi, 1986) have reported no change after i.v. administration of insulin. Others (Stevenson et al. 1987 ) observed a decrease of about 50% after intraportal infusion of insulin. The different routes of administration of insu¬ lin may be responsible for the different results. After oral administration of insulin, which is equivalent to intraportal injection, there was a sharp and consistent fall in plasma GLI. Insulin in the lumen of the gas¬ trointestinal tract may also act directly on the GLIproducing cells of the gut to suppress secretion. The demonstration of insulin receptors on the lumenal side of the intestinal mucosa (Pillion, Ganapathy & Leibach, 1985) suggests that insulin in the intestine may modulate intestinal function in some way.
Although the radioimmunoassay of glucagon was carried out with an antiserum said to be specific for pancreatic glucagon, the high values after pancreatectomy suggest that other molecular species may be included in the assay. The consistent decrease in values after oral insulin could result either from a direct inhibition by insulin in the intestine of the secretion of glucagon from cells in the gut, or indirectly from the decrease in plasma glucose. Future studies should investigate more closely the identity of the species of glucagon that responds to the oral administration of insulin.
Pancreatic digestive enzymes Total pancreatectomy also eliminates the source of lumenal digestive enzymes in the small intestine. In compensation, our dogs were maintained on a diet to which digestive enzymes were added. Because food and digestive enzymes were not available the day of the experiment the lack of proteases may have con¬ tributed to the survival of insulin delivered to the small intestine in uncoated capsules (Fig. 2) or even in coated capsules that may have opened prematurely. In two preliminary experiments decreases in plasma levels of glucose were observed after administration of insulin in azopolymer-coated capsules to normal dogs with intact supplies of pancreatic enzymes.
